Hypertension
Conditions
Brief summary
The aim of this study is to investigate the antihypertensive effects of Mei-Gin formula-4 (MGF-4) and Mei-Gin formula-7.
Detailed description
It's a randomized, and single-blind trial and was designed to evaluate the effects of MGFs (MGF-4 and MGF-4) on blood pressure. 50 participants with hypertension (systolic blood pressure between 130-179 mmHg or diastolic blood pressure between 85-109 mmHg) who did not accept any hypertension medication were randomized allocated to either MGF-4 or MGF-7 group. Participants were instructed to take 4 capsules of MGF-4 or MGF-7 daily throughout the duration of the 8 weeks intervention study. After treatment, the change of the blood pressure and relative mechanism were analyzed.
Interventions
DIETARY_SUPPLEMENTMGF-4
Participants were instructed to take 2 capsules of MGF-4 twice a day, and measure own blood pressure at morning everyday throughout the duration of the study.
DIETARY_SUPPLEMENTMGF-7
Participants were instructed to take 2 capsules of MGF-7 twice a day, and measure own blood pressure at morning everyday throughout the duration of the study.
Sponsors
Chung Shan Medical University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* The age of the subject is 20 to 70 years old. * The subject is a patient with hypertension (SBP is between 130-179 mmHg, DBP is between 85-109mmHg, one of the two can be diagnosed), and there are no serious illnesses requiring hospitalization during the study period treatment. * No hypertension medication. * The subject can understand the test process described in the consent form and the possible potential risks and benefits, and able to sign the consent form. * The subjects shall observe diet control during the trial period.
Exclusion criteria
* Subjects diagnosed with cancer and still under active treatment. * Subjects diagnosed with heart disease and still under active treatment. * Other drugs are used, whose pharmacological effects may affect blood pressure or may aggravate the effects of drugs. * Subjects who have systemic infection and need systemic antibiotics.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change the blood pressure after intervention | Week 0, 4 and 8 | Compare the difference of own SBP and DBP between the week 0, 4 and 8 in each groups |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline serum MDA and TEAC at Week 8 | Week 0 and 8 | Compare the difference of serum MDA and TEAC between week 0 and 8 |
Countries
Taiwan
Outcome results
None listed